Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aimmax Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners but 1 distinct art unit. The examination work is therefore divided between examiners within a common art-unit setting.
BEANE, RANDALL L is the busiest examiner, with 1 pending matter. The current assignments do not show both matters under that examiner. Counsel can use the shared art-unit context to look for consistent technical treatment, while preserving separate response strategies for the claim and disclosure issues presented in each biotechnology and pharmaceutical matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687807 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687807 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | BEANE, RANDALL L | — |
| 18561857 | PRISTINAMYCIN IA AND FLOPRISTIN COMBINATIONS IN TREATING OR PREVENTING BACTERIAL INFECTIONS | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687807 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | BEANE, RANDALL L | — | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18561857 | PRISTINAMYCIN IA AND FLOPRISTIN COMBINATIONS IN TREATING OR PREVENTING BACTERIAL INFECTIONS | BOWLES, DAVID PAUL | 1654 | §103 | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAimmax Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Randall L Beane has the most, with 1 of Aimmax Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
